Table 1.

Properties of uricase-based molecules examined in the clinical and research settings

	Uricase molecule			References
	Pegloticase	Pegadricase	Rasburicase
Molecular weight	540 kDa	304.34 g/mol	34 kDa	[8, 33, 65]
Origin	Pig-baboon chimeric uricase cDNA amplified in Escherichia coli	Candida utilis	Saccharomyces cerevisiae and Aspergillus flavus	[11, 25, 30, 33, 34]
Disease	Chronic refractory gout	Chronic refractory gout	Hyperuricemia in acute tumor lysis syndrome	[8, 11, 25, 26, 30, 32–34, 39]
Dosing (route of administration)	8 mg (IV) every 2 weeks	0.2 or 0.4 mg/kg (IV) monthly	0.2 mg/kg (IV) daily for up to 5–7 daysa	[8, 26, 32, 33, 37]
Half-life	6.4–13.8 days	3 days	16–22 h	[9, 11, 33, 37]

IV intravenously

^aDosing specific to patients with hyperuricemia secondary to tumor lysis syndrome.